Effectiveness of Palbociclib with Aromatase Inhibitors for the Treatment of Advanced Breast Cancer in an Exposure Retrospective Cohort Study: Implications for Clinical Practice

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2023 Jun 29

PMID 37386484

Authors

Filipa Alves da Costa

Fabio Cardoso Borges

Adriana Ramos

Alexandra Mayer

Claudia Brito

Catarina Ramos

Catarina Bernardo

Mariane Cossito

Claudia Furtado

Arlindo R Ferreira

Diogo Martins-Branco

Ana da Costa Miranda

Antonio Lourenco

Affiliations

Soon will be listed here.

Abstract

Background: New drugs for locally advanced or metastatic breast cancer have led to clinical benefits, aside with increasing costs to healthcare systems. The current financing model for health technology assessment (HTA) privileges real-world data. As part of the ongoing HTA, this study aimed to evaluate the effectiveness of palbociclib with aromatase inhibitors (AI) and compare it with the efficacy reported in PALOMA-2.

Methods: A population-based retrospective exposure cohort study was conducted including all patients initiating treatment in Portugal with palbociclib under early access use and registered in the National Oncology Registry. The primary outcome was progression free survival (PFS). Secondary outcomes considered included time to palbociclib failure (TPF), overall survival (OS), time to next treatment (TTNT), and proportion of patients discontinuing treatment due to adverse events (AEs). The Kaplan-Meier method was used and median, 1- and 2-year survival rates were computed, with two-sided 95% confidence intervals (95%CI). STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines for reporting observational studies were used.

Results: There were 131 patients included. Median follow-up was 28.3 months (IQR: 22.7-35.2) and median duration of treatment was 17.5 months (IQR: 7.8-29.1). Median PFS was 19.5 months (95%CI 14.2-24.2), corresponding to a 1-year PFS rate of 67.9% (95%CI 59.2-75.2) and a 2-year PFS rate of 42.0% (95%CI 33.5-50.3). Sensitivity analysis showed median PFS would increase slightly when excluding those not initiating treatment with the recommended dose, raising to 19.8 months (95%CI 14.4-28.9). By considering only patients meeting PALOMA-2 criteria, we could observe a major difference in treatment outcomes, with a mean PFS of 28.8 months (95%CI 19.4-36.0). TPF was 19.8 months (95%CI 14.2-24.9). Median OS was not reached. Median TTNT was 22.5 months (95%CI 18.0-29.8). A total of 14 patients discontinued palbociclib because of AEs (10.7%).

Conclusions: Data suggest palbociclib with AI to have an effectiveness of 28.8 months, when used in patients with overlapping characteristics to those used in PALOMA-2. However, when used outside of these eligibility criteria, namely in patients with less favorable prognosis (e.g., presence of visceral disease), the benefits are inferior, even though still favorable.

Citing Articles

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies.

Su H, Lin H, Tam K Target Oncol. 2024; 20(1):71-88.

PMID: 39656361 DOI: 10.1007/s11523-024-01118-0.

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or....

Yoshinami T, Nagai S, Hattori M, Okamura T, Watanabe K, Nakayama T Breast Cancer. 2024; 31(4):621-632.

PMID: 38642245 PMC: 11194199. DOI: 10.1007/s12282-024-01575-5.

Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution.

Teodoro M, Mayer A, da Costa Miranda A, Nunes H, Alves da Costa F, Lourenco A J Pharm Policy Pract. 2024; 17(1):2296551.

PMID: 38250517 PMC: 10798277. DOI: 10.1080/20523211.2023.2296551.

References

Wilkie J, Schickli M, Berger M, Lustberg M, Reinbolt R, Noonan A . Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. Clin Breast Cancer. 2019; 20(1):33-40. DOI: 10.1016/j.clbc.2019.06.010. View

Templeton A, Booth C, Tannock I . Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. J Clin Oncol. 2020; 38(15):1651-1654. DOI: 10.1200/JCO.19.02035. View

Phillips C, Parmar A, Guo H, Schwartz D, Isaranuwatchai W, Beca J . Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. Cancer. 2020; 126(8):1717-1726. DOI: 10.1002/cncr.32697. View

Palumbo R, Torrisi R, Sottotetti F, Presti D, Gambaro A, Collova E . Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study. Ther Adv Med Oncol. 2021; 13:1758835920987651. PMC: 7970542. DOI: 10.1177/1758835920987651. View

Murteira R, Borges F, Mendes G, Ramos C, Ramos A, Soares P . Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort study. Pharmacoepidemiol Drug Saf. 2020; 29(10):1295-1302. DOI: 10.1002/pds.5091. View

Azoulay L . Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective. Oncologist. 2022; 27(9):e731-e738. PMC: 9438907. DOI: 10.1093/oncolo/oyac114. View

Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M . Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer. 2018; 96:17-24. DOI: 10.1016/j.ejca.2018.03.015. View

Lucas R, Azevedo A, Barros H . Self-reported data on reproductive variables were reliable among postmenopausal women. J Clin Epidemiol. 2008; 61(9):945-50. DOI: 10.1016/j.jclinepi.2007.11.001. View

Grinda T, Antoine A, Jacot W, Blaye C, Cottu P, Dieras V . Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open. 2021; 6(3):100114. PMC: 8095121. DOI: 10.1016/j.esmoop.2021.100114. View

10.

Varella L, Samuel Eziokwu A, Jia X, Kruse M, Moore H, Budd G . Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat. 2019; 176(2):429-434. DOI: 10.1007/s10549-019-05176-1. View

11.

Taylor-Stokes G, Mitra D, Waller J, Gibson K, Milligan G, Iyer S . Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS.... Breast. 2018; 43:22-27. DOI: 10.1016/j.breast.2018.10.009. View

12.

Amaro C, Batra A, Lupichuk S . First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta. Curr Oncol. 2021; 28(3):2270-2280. PMC: 8293123. DOI: 10.3390/curroncol28030209. View

13.

Aguiar J, Borges F, Murteira R, Ramos C, Gouveia E, Passos M . Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma. Int J Clin Pharm. 2018; 40(4):852-861. DOI: 10.1007/s11096-018-0665-1. View

14.

Ouyang Q, Li S, Gao M, Zhu L, Xu S, Meng S . Risk factors associated with loss to follow-up of breast cancer patients: A retrospective analysis. Breast. 2021; 57:36-42. PMC: 7970119. DOI: 10.1016/j.breast.2021.02.012. View

15.

Sievers H, Joos A, Hiligsmann M . Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements. Int J Technol Assess Health Care. 2021; 37:e40. DOI: 10.1017/S0266462321000131. View

16.

Brown E, Wood L, Wood S . The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999; 20(2):109-17. DOI: 10.2165/00002018-199920020-00002. View

17.

Rugo H, Finn R, Dieras V, Ettl J, Lipatov O, Joy A . Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019; 174(3):719-729. PMC: 6438948. DOI: 10.1007/s10549-018-05125-4. View

18.

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro M, Andre F . 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12):1623-1649. PMC: 7510449. DOI: 10.1016/j.annonc.2020.09.010. View

19.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344-9. DOI: 10.1016/j.jclinepi.2007.11.008. View

20.

Waller J, Mitra D, Mycock K, Taylor-Stokes G, Milligan G, Zhan L . Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. J Glob Oncol. 2019; 5:JGO1800239. PMC: 6550052. DOI: 10.1200/JGO.18.00239. View